Skip to content
ClinCalc Pro
Menu
Combined vaccine (Td/IPV)

Diphtheria with tetanus and poliomyelitis vaccine

Brand names: Revaxis

This is a combined diphtheria, tetanus and inactivated poliomyelitis (Td/IPV) vaccine, used in the UK childhood and adolescent programme as the pre-school or teenage booster and for primary immunisation in older individuals.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It contains diphtheria and tetanus toxoids with inactivated poliovirus antigens that stimulate protective antibody responses without causing the diseases.

Prescribing in practice

  • Defer in anyone with a confirmed anaphylactic reaction to a previous dose or a vaccine component, and postpone routinely if the child is acutely unwell with fever.
  • Give by intramuscular injection and never administer the lower-antigen Td/IPV preparation where a higher-antigen primary schedule is specifically indicated for the child's age.
  • Record the dose and schedule position; minor illness without fever is not a reason to delay.

Monitoring

Observe briefly after vaccination for immediate hypersensitivity and advise on expected local reactions such as soreness, redness and swelling.

Counselling the patient

  • Mild fever and a sore arm are common and settle within a day or two.
  • Seek advice if a severe or unusual reaction occurs.
  • Keep the child's immunisation record up to date.

Evidence & guidelines

The Td/IPV vaccine is used as the adolescent booster in the UK routine immunisation schedule as set out in national guidance (the Green Book).

Reference: UKHSA Green Book; NHS England immunisation schedule; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.